Type I Interferon Predicts an Alternate Immune System Phenotype in Systemic Lupus Erythematosus.
Journal
ACR open rheumatology
ISSN: 2578-5745
Titre abrégé: ACR Open Rheumatol
Pays: United States
ID NLM: 101740025
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
31
03
2019
accepted:
30
07
2019
entrez:
29
11
2019
pubmed:
30
11
2019
medline:
30
11
2019
Statut:
epublish
Résumé
Type I interferon (IFN) is important to systemic lupus erythematosus (SLE) pathogenesis, but it is not clear how chronic elevations in IFN alter immune function. We compared cytokine responses after whole blood stimulation with Toll-like receptor (TLR) agonists in high- and low-IFN SLE patient subgroups. SLE patients and nonautoimmune controls were recruited, and SLE patients were categorized as either high or low IFN. Whole blood was dispensed into tubes coated with lipopolysaccharide (LPS), oligonucleotides with cytosine-guanine repeats, Resiquimod, IFN-α, and IFN-α + LPS. Cytokine production in patient sera and after whole blood TLR stimulation was measured by multiplex assay, and type I IFN was assessed using a functional assay. Circulating plasmacytoid dendritic cell numbers were specifically reduced in high-IFN SLE patients and not in low-IFN SLE patients. In serum, we observed that the correlations between cytokines in serum differed to a much greater degree between the high- and low-IFN groups ( We find striking differences in resting and stimulated cytokine patterns in high- vs. low-IFN SLE patients, which supports the biological importance of these patient subsets. These data could inform personalized treatment approaches and the pathogenesis of SLE flare following infection.
Identifiants
pubmed: 31777831
doi: 10.1002/acr2.11073
pmc: PMC6858011
doi:
Types de publication
Journal Article
Langues
eng
Pagination
499-506Informations de copyright
© 2019 The Authors. ACR Open Rheumatology published by Wiley Periodicals, Inc. on behalf of American College of Rheumatology.
Références
J Autoimmun. 1998 Oct;11(5):465-70
pubmed: 9802930
Ann Rheum Dis. 2005 Dec;64(12):1692-7
pubmed: 15843451
Genes Immun. 2015 Jan-Feb;16(1):15-23
pubmed: 25338677
Curr Opin Rheumatol. 2015 Sep;27(5):440-7
pubmed: 26218512
Arthritis Rheum. 2011 Apr;63(4):1044-53
pubmed: 21162028
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2610-5
pubmed: 12604793
Clin Rev Allergy Immunol. 2011 Feb;40(1):42-9
pubmed: 20063186
Front Immunol. 2013 Oct 01;4:309
pubmed: 24101921
Lupus. 2009 Oct;18(11):980-9
pubmed: 19762399
Proc Natl Acad Sci U S A. 2018 Jan 16;115(3):E488-E497
pubmed: 29282317
Am J Pathol. 2001 Jul;159(1):237-43
pubmed: 11438470
Arthritis Rheum. 2011 Dec;63(12):3931-41
pubmed: 22127709
J Autoimmun. 2015 Jun;60:51-58
pubmed: 25921064
J Neurol Sci. 2012 Feb 15;313(1-2):48-53
pubmed: 22036215
PLoS Med. 2006 Dec;3(12):e491
pubmed: 17177599
Genes Immun. 2007 Sep;8(6):492-502
pubmed: 17581626
Autoimmunity. 2003 Dec;36(8):473-9
pubmed: 14984024
Nat Immunol. 2018 Mar;19(3):302-314
pubmed: 29476184
Nat Rev Rheumatol. 2018 Mar 21;14(4):214-228
pubmed: 29559718
Arthritis Rheum. 2008 Jul;58(7):2113-9
pubmed: 18576315
Arthritis Res Ther. 2010;12(4):R151
pubmed: 20659327
Arthritis Rheum. 1997 Sep;40(9):1725
pubmed: 9324032
Arthritis Rheum. 2005 May;52(5):1491-503
pubmed: 15880830
Lupus Sci Med. 2017 Jun 25;4(1):e000202
pubmed: 29238602
Pharmaceut Med. 2017 Apr;31(2):81-88
pubmed: 28827978
Arthritis Rheumatol. 2017 Jun;69(6):1257-1266
pubmed: 28257602
Autoimmunity. 2003 Dec;36(8):481-90
pubmed: 14984025
Arthritis Rheum. 2006 Jun;54(6):1906-16
pubmed: 16736505
Nat Rev Rheumatol. 2016 Jul;12(7):377-8
pubmed: 27225301
Pediatrics. 2011 May;127(5):e1239-46
pubmed: 21502224
Arthritis Rheum. 2012 Sep;64(9):2947-52
pubmed: 22488302